announced it would exercise its right to acquire Vitaeris. In December 2021 the business announced it would acquire Swiss drugmaker, Vifor Pharma AG, for $11.7 billion. In August 2022 CSL rebranded all of its divisions to start with the CSL name. Therefore, the divisions became CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor. Acquisition history CSL Limited (Founded 1916 as Commonwealth Serum Laboratories) ZLB Behring ZLB Bioplasma AG (Acq 2000) Aventis Behring (Acq 2004) Vifor Pharma (Acq 2021) Seqirus (Merged 2014) BioCSL Novartis Influenza Vaccines div. Calimmune (Acq 2017) Vitaeris (Acq 2020) Locations The company's headquarters remain in Parkville, Victoria, an inner suburb of Melbourne, and has offices and laboratory space in Sydney. CSL Behring is headquartered in King of Prussia, USA and it has manufacturing operations and R&D laboratories in Broadmeadows, Victoria, the Swiss city of Bern, in Marburg in Germany, and Kankakee, USA. Seqirus has its headquarters in Maidenhead and has production facilities in Holly Springs, US, Liverpool, UK, and Parkville, Victoria Vaccines A/H1N1 2009 pandemic CSL's vaccine for swine flu, the world's first, was approved in September 2009 for use by people over age 10. The federal government ordered 21million doses of vaccine for Australians. CSL also provided vaccines for customers in Singapore and the US. On 28 September 2010, the Australian Therapeutic Goods Administration conducted an analysis of febrile convulsions following immunisation in children following monovalent pandemic H1N1 vaccine (Panvax/Panvax Junior, CSL). A paper published in the Medical Journal of Australia provides a possible reason for CSL's 2010 flu vaccine causing febrile convulsions in children. The authors hypothesise that suboptimal use of the detergent called deoxycholate – used in the manufacturing process by CSL (one of the few vaccine manufacturers that use it) – to split the flu virus from its membrane may be at fault. https://www.mja.com.au/system/files/issues/195_06_190911/kel10941_fm.pdf COVID-19 pandemic On 7 September 2020, CSL signed agreements with the Australian government to supply the University of Queensland vaccine (V451) and to manufacture (with AstraZeneca) the Oxford University vaccine (AZD1222), which would yield nearly 85 million doses for Australians. The agreement was contingent on the future success of clinical trials of these vaccines. Most of the manufacture would occur in Melbourne, Australia. On 11 December 2020, after a high percentage of the University of Queensland vaccine trial participants returned "false positive" results for HIV, it was decided that vaccine development will not proceed to Phase 2/3 trials.